{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Virus spumeux simien : Questions médicales les plus fréquentes",
"headline": "Virus spumeux simien : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Virus spumeux simien : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-15",
"dateModified": "2025-05-10",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Virus spumeux simien"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Spumavirus",
"url": "https://questionsmedicales.fr/mesh/D016092",
"about": {
"@type": "MedicalCondition",
"name": "Spumavirus",
"code": {
"@type": "MedicalCode",
"code": "D016092",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.820.650.850"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Virus spumeux simien",
"alternateName": "Simian foamy virus",
"code": {
"@type": "MedicalCode",
"code": "D053150",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Antoine Gessain",
"url": "https://questionsmedicales.fr/author/Antoine%20Gessain",
"affiliation": {
"@type": "Organization",
"name": "Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Institut Pasteur, UMR3569 CNRS, Paris, France."
}
},
{
"@type": "Person",
"name": "Florence Buseyne",
"url": "https://questionsmedicales.fr/author/Florence%20Buseyne",
"affiliation": {
"@type": "Organization",
"name": "Institut Pasteur, Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Institut Pasteur, 28 rue du Dr Roux, 75015, Paris, France; UMR CNRS 3569, Institut Pasteur, 28 rue du Dr Roux, 75015, Paris, France. Electronic address: florence.buseyne@pasteur.fr."
}
},
{
"@type": "Person",
"name": "Juan Tan",
"url": "https://questionsmedicales.fr/author/Juan%20Tan",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Molecular Microbiology and Technology, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, 300071, China."
}
},
{
"@type": "Person",
"name": "Martin Löchelt",
"url": "https://questionsmedicales.fr/author/Martin%20L%C3%B6chelt",
"affiliation": {
"@type": "Organization",
"name": "German Cancer Research Center DKFZ, Program Infection, Inflammation and Cancer, Division of Viral Transformation Mechanisms, 69120 Heidelberg, Germany."
}
},
{
"@type": "Person",
"name": "Wentao Qiao",
"url": "https://questionsmedicales.fr/author/Wentao%20Qiao",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Molecular Microbiology and Technology, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, 300071, China. wentaoqiao@nankai.edu.cn."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "DNA Methylation in the Fields of Prenatal Diagnosis and Early Detection of Cancers.",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37511475",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms241411715"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.",
"datePublished": "2023-03-07",
"url": "https://questionsmedicales.fr/article/36894035",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1053/j.gastro.2023.02.044"
}
},
{
"@type": "ScholarlyArticle",
"name": "Early detection of cancer therapy cardiotoxicity by radionuclide angiography: An update.",
"datePublished": "2023-02-28",
"url": "https://questionsmedicales.fr/article/36855007",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12350-023-03202-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Optimal age to stop prostate cancer screening and early detection.",
"datePublished": "2023-08-19",
"url": "https://questionsmedicales.fr/article/37598870",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jcpo.2023.100443"
}
},
{
"@type": "ScholarlyArticle",
"name": "Serum IgG N-glycans enable early detection and early relapse prediction of colorectal cancer.",
"datePublished": "2022-10-03",
"url": "https://questionsmedicales.fr/article/36121650",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ijc.34298"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Virus",
"item": "https://questionsmedicales.fr/mesh/D014780"
},
{
"@type": "ListItem",
"position": 3,
"name": "Virus à ARN",
"item": "https://questionsmedicales.fr/mesh/D012328"
},
{
"@type": "ListItem",
"position": 4,
"name": "Retroviridae",
"item": "https://questionsmedicales.fr/mesh/D012190"
},
{
"@type": "ListItem",
"position": 5,
"name": "Spumavirus",
"item": "https://questionsmedicales.fr/mesh/D016092"
},
{
"@type": "ListItem",
"position": 6,
"name": "Virus spumeux simien",
"item": "https://questionsmedicales.fr/mesh/D053150"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Virus spumeux simien - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Virus spumeux simien",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Virus spumeux simien",
"description": "Comment diagnostiquer une infection par le SFV ?\nQuels tests sont utilisés pour le SFV ?\nLe SFV peut-il être détecté chez l'homme ?\nQuels échantillons sont nécessaires pour le diagnostic ?\nLe SFV est-il transmissible entre espèces ?",
"url": "https://questionsmedicales.fr/mesh/D053150?mesh_terms=Early+Detection+of+Cancer&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Virus spumeux simien",
"description": "Quels sont les symptômes d'une infection par le SFV ?\nLe SFV cause-t-il des maladies chez les primates ?\nY a-t-il des symptômes chez les humains infectés ?\nLe SFV peut-il provoquer des symptômes neurologiques ?\nLe SFV est-il associé à d'autres infections ?",
"url": "https://questionsmedicales.fr/mesh/D053150?mesh_terms=Early+Detection+of+Cancer&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Virus spumeux simien",
"description": "Comment prévenir l'infection par le SFV ?\nLes vaccins existent-ils contre le SFV ?\nLe SFV se propage-t-il par contact humain ?\nQuelles précautions prendre avec les primates ?\nLes tests de dépistage sont-ils recommandés ?",
"url": "https://questionsmedicales.fr/mesh/D053150?mesh_terms=Early+Detection+of+Cancer&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Virus spumeux simien",
"description": "Quel traitement existe pour le SFV ?\nLe SFV nécessite-t-il un traitement préventif ?\nLes antiviraux sont-ils efficaces contre le SFV ?\nLe SFV nécessite-t-il une surveillance médicale ?\nY a-t-il des traitements expérimentaux pour le SFV ?",
"url": "https://questionsmedicales.fr/mesh/D053150?mesh_terms=Early+Detection+of+Cancer&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Virus spumeux simien",
"description": "Quelles complications peuvent survenir avec le SFV ?\nLe SFV est-il lié à d'autres maladies ?\nLe SFV peut-il affecter le système immunitaire ?\nY a-t-il des risques de cancer liés au SFV ?\nLe SFV peut-il causer des infections opportunistes ?",
"url": "https://questionsmedicales.fr/mesh/D053150?mesh_terms=Early+Detection+of+Cancer&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Virus spumeux simien",
"description": "Qui est à risque d'infection par le SFV ?\nLes travailleurs de laboratoire sont-ils à risque ?\nLes voyageurs dans des zones endommagées sont-ils à risque ?\nLes personnes ayant des animaux de compagnie sont-elles à risque ?\nLes personnes immunodéprimées sont-elles plus à risque ?",
"url": "https://questionsmedicales.fr/mesh/D053150?mesh_terms=Early+Detection+of+Cancer&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection par le SFV ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par des tests sérologiques ou PCR pour détecter le virus."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le SFV ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests ELISA et PCR sont couramment utilisés pour identifier le SFV."
}
},
{
"@type": "Question",
"name": "Le SFV peut-il être détecté chez l'homme ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anticorps contre le SFV ont été trouvés chez des humains, mais sans symptômes."
}
},
{
"@type": "Question",
"name": "Quels échantillons sont nécessaires pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des échantillons de sang ou de tissus peuvent être nécessaires pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Le SFV est-il transmissible entre espèces ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le SFV est principalement transmis entre primates, mais des cas chez l'homme sont possibles."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une infection par le SFV ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le SFV est généralement asymptomatique chez les hôtes, y compris les primates et les humains."
}
},
{
"@type": "Question",
"name": "Le SFV cause-t-il des maladies chez les primates ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, le SFV ne cause pas de maladies cliniques chez les primates infectés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes chez les humains infectés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les humains infectés par le SFV ne présentent généralement aucun symptôme clinique."
}
},
{
"@type": "Question",
"name": "Le SFV peut-il provoquer des symptômes neurologiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune preuve ne montre que le SFV provoque des symptômes neurologiques chez l'homme."
}
},
{
"@type": "Question",
"name": "Le SFV est-il associé à d'autres infections ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le SFV peut coexister avec d'autres infections virales, mais sans lien direct."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'infection par le SFV ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le contact avec des primates infectés est la meilleure prévention contre le SFV."
}
},
{
"@type": "Question",
"name": "Les vaccins existent-ils contre le SFV ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de vaccin spécifique contre le SFV, car il est généralement inoffensif."
}
},
{
"@type": "Question",
"name": "Le SFV se propage-t-il par contact humain ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "La transmission interhumaine du SFV est rare et non documentée dans la littérature."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre avec les primates ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez de manipuler des primates sauvages et respectez les protocoles de sécurité."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage sont-ils recommandés ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de dépistage ne sont pas recommandés pour la population générale, car asymptomatique."
}
},
{
"@type": "Question",
"name": "Quel traitement existe pour le SFV ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement spécifique pour le SFV, car il est généralement asymptomatique."
}
},
{
"@type": "Question",
"name": "Le SFV nécessite-t-il un traitement préventif ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, aucun traitement préventif n'est nécessaire en raison de l'absence de symptômes."
}
},
{
"@type": "Question",
"name": "Les antiviraux sont-ils efficaces contre le SFV ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antiviraux ne sont pas utilisés contre le SFV, car il ne cause pas de maladie."
}
},
{
"@type": "Question",
"name": "Le SFV nécessite-t-il une surveillance médicale ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance n'est pas nécessaire, car le SFV est généralement inoffensif."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux pour le SFV ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'y a pas de traitements expérimentaux spécifiques pour le SFV."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le SFV ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le SFV ne cause pas de complications cliniques connues chez les hôtes infectés."
}
},
{
"@type": "Question",
"name": "Le SFV est-il lié à d'autres maladies ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune association directe entre le SFV et d'autres maladies n'a été établie."
}
},
{
"@type": "Question",
"name": "Le SFV peut-il affecter le système immunitaire ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de preuve que le SFV affecte le système immunitaire des hôtes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de cancer liés au SFV ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune preuve ne lie le SFV à un risque accru de cancer chez les hôtes infectés."
}
},
{
"@type": "Question",
"name": "Le SFV peut-il causer des infections opportunistes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le SFV n'est pas connu pour causer des infections opportunistes chez les hôtes."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'infection par le SFV ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes en contact étroit avec des primates sont à risque d'infection par le SFV."
}
},
{
"@type": "Question",
"name": "Les travailleurs de laboratoire sont-ils à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les chercheurs manipulant des primates ou des échantillons de SFV sont à risque."
}
},
{
"@type": "Question",
"name": "Les voyageurs dans des zones endommagées sont-ils à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyageurs dans des zones avec des primates sauvages peuvent être à risque."
}
},
{
"@type": "Question",
"name": "Les personnes ayant des animaux de compagnie sont-elles à risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le risque est faible, mais les personnes avec des primates comme animaux de compagnie sont à risque."
}
},
{
"@type": "Question",
"name": "Les personnes immunodéprimées sont-elles plus à risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de preuve que les personnes immunodéprimées soient plus à risque d'infection par le SFV."
}
}
]
}
]
}
The central objective of the metamorphosis of discovery science into biomedical applications is to serve the purpose of patients and curtail the global disease burden. The journey from the discovery o...
Diagnosing gastric cancer (GC) while the disease remains eligible for surgical resection is challenging. In view of this clinical challenge, novel and robust biomarkers for early detection thus improv...
The present 3-step study incorporated data from 2141 patients, including 888 with GC, 158 with chronic atrophic gastritis, 193 with intestinal metaplasia, 501 healthy donors, and 401 with other gastro...
In discovery phase, one LR (GClnc1) was found to be up-regulated in both tissue and circulating EV samples with an area under the curve (AUC) of 0.9369 (95% confidence interval [CI], 0.9073-0.9664) fo...
EV-derived GClnc1 serves as a circulating biomarker for the early detection of GC, thus providing opportunities for curative surgery and improved survival outcomes....
Cancer therapy-induced cardiotoxicity is an emerging clinical and healthcare issue. Myocardial dysfunction and heart failure are mostly responsible for increased cardiovascular mortality in cancer dis...
Prostate Cancer screening should be discontinued at older ages because competing mortality risks eventually dominate the risk of Prostate Cancer and harms exceed benefits. We explored the Prostate Can...
We applied Bellman Equations to formulate the net benefits biopsy and "do nothing". Using difference between the net benefits of two alternatives, we calculated the stopping age. The cancer states wer...
Our results suggested that Prostate Cancer screening stopping ages from the patient, healthcare system, and social were 70, 68, and 68 respectively. The univariate sensitivity analysis showed that the...
Men should not be screened for Prostate Cancer beyond 70 years old, as this results in the net benefit of "do nothing" above the biopsy. Nevertheless, this finding needs to be further studied with mor...
Colorectal cancer (CRC) develops mainly from colorectal advanced adenomas (AA), which are considered precancerous lesions. Novel early diagnostic biomarkers are urgently needed to distinguish CRC and ...
The modality to detect ovarian cancer at an early stage is very limited. Early diagnosis determines the prognosis. This study aimed to develop a risk assessment tool for early detection of ovarian can...
This study was carried out as a cohort study of patients diagnosed with suspected ovarian tumors undergoing cytoreduction operation at Hasan Sadikin Hospital, Bandung, from December 2019 to September ...
In total, 115 patients included in this study. The differences were statistically significant in terms of the six variables (abdominal bloating, nausea/vomiting, decreased of appetite, fullness, menst...
Risk assessments based on ovarian cancer self-assessment unfortunately were not comparable to postoperative histopathology as a single predictor. Ten variables in ovarian cancer artificial intelligenc...
Early detection of colorectal cancer (CRC) significantly enhances patient outcomes. Conventional CRC screening tools, like endoscopy and stool-based tests, have constraints due to their invasiveness o...
In this research, we harnessed the Mutation Capsule Plus (MCP) technology to profile an array of genomic characteristics from cfDNA procured from a single blood draw. This profiling encompassed DNA me...
This model was subsequently validated in another cohort comprising 89 CRC patients and 95 healthy controls. Remarkably, the model achieved an area under the curve (AUC) of 0.981 (95% confidence interv...
Our findings underscore the clinical potential of our multiomics liquid biopsy test, indicating its prospective role as a noninvasive method for early-stage CRC detection. This multiomics approach hol...
Clinical diagnostics rely heavily on the detection and quantification of cancer biomarkers. The rapid detection of cancer-specific biomarkers is of great importance in the early diagnosis of cancers a...
A cell-free DNA (cfDNA) assay would be a promising approach to early cancer diagnosis, especially for patients with dense tissues. Consistent cfDNA signatures have been observed for many carcinogens. ...
Hepatocellular carcinoma (HCC) is the fastest-rising and fourth most common cause of cancer death worldwide. Liver cirrhosis is the largest underlying risk factor for HCC. Therefore, patients with cir...
This is a UK-based prospective, longitudinal, diagnostic, prognostic, multicentre, non-CTIMP study. Aiming to recruit 3000 patients with liver cirrhosis without a HCC diagnosis, the Pearl cohort will ...
Ethical approval has been granted by REC and the trial is registered on ClinicalTrials.gov. The results will be published in peer-reviewed journals and presented at relevant meetings....
NCT05541601....